Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm, Multi-center Trial of Cabozantinib for Progressive Hepatocellular Carcinoma (HCC) Post-first-line Immuno-oncologic Combination Therapy (CAPIO Study)

NCT07151326 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT07151326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07151326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm, Multi-center Trial of Cabozantinib for Progressive Hepatocellular Carcinoma (HCC) Post-first-line Immuno-oncologic Combination Therapy (CAPIO Study)
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
June 30, 2028
Enrollment
60 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)